Loading...
XNASSWKHL
Market cap196mUSD
Dec 24, Last price  
25.28USD
1D
0.32%
1Q
-0.47%
Name

SWK Holdings Corp

Chart & Performance

D1W1MN
XNAS:SWKHL chart
P/E
19.47
P/S
8.19
EPS
1.30
Div Yield, %
0.00%
Shrs. gr., 5y
-0.55%
Rev. gr., 5y
7.76%
Revenues
38m
-8.98%
48,900,00043,128,00054,030,00060,794,00065,219,00045,258,00000637,0006,447,00017,400,00023,460,00022,380,00037,486,00025,990,00030,747,00036,712,00056,155,00041,484,00037,760,000
Net income
16m
+17.76%
-21,768,000-17,966,000-2,426,000-8,021,000-3,655,00034,893,000-707,000-1,066,000-1,421,00012,862,00020,765,000-7,370,00028,888,0003,047,0006,195,00023,828,0005,202,00025,929,00013,491,00015,887,000
CFO
15m
+81.50%
-13,073,000-16,263,000-1,661,000-8,433,000-418,000-2,044,000-1,310,000-1,225,000-1,115,0001,344,0005,125,00011,209,0009,643,00019,458,00019,626,00018,536,00019,268,00034,295,0008,202,00014,887,000
Earnings
Mar 18, 2025

Profile

SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endocrine disease. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
URL
https://www.swkhold.com/
IPO date
Sep 22, 1999
Employees
23
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
37,760
-8.98%
41,484
-26.13%
56,155
52.96%
Cost of revenue
14,668
26,868
28,314
Unusual Expense (Income)
NOPBT
23,092
14,616
27,841
NOPBT Margin
61.15%
35.23%
49.58%
Operating Taxes
(1,274)
(4,000)
7,082
Tax Rate
25.44%
NOPAT
24,366
18,616
20,759
Net income
15,887
17.76%
13,491
-47.97%
25,929
398.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
(6,327)
(1,138)
(368)
BB yield
2.84%
0.50%
0.15%
Debt
Debt current
2,445
8
Long-term debt
43,131
33
185
Deferred revenue
33
185
Other long-term liabilities
6,864
13,312
10,149
Net debt
38,580
(3,754)
(47,314)
Cash flow
Cash from operating activities
14,887
8,202
34,295
CAPEX
(496)
(297)
(1,078)
Cash from investing activities
(48,948)
(43,548)
25,761
Cash from financing activities
33,140
(1,361)
(20,201)
FCF
21,652
18,249
20,191
Balance
Cash
4,503
6,156
43,897
Long term investments
48
76
3,610
Excess cash
2,663
4,158
44,699
Stockholders' equity
(4,144,789)
(4,154,704)
(3,941,136)
Invested Capital
4,475,099
4,450,456
4,218,899
ROIC
0.55%
0.43%
0.49%
ROCE
6.99%
4.94%
10.03%
EV
Common stock shares outstanding
12,696
12,880
12,834
Price
17.53
-0.62%
17.64
-10.14%
19.63
36.41%
Market cap
222,561
-2.04%
227,203
-9.82%
251,931
36.12%
EV
261,141
219,738
160,728
EBITDA
26,002
17,444
31,902
EV/EBITDA
10.04
12.60
5.04
Interest
1,849
340
374
Interest/NOPBT
8.01%
2.33%
1.34%